Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Patent
1996-09-26
2000-11-14
Yasko, John D.
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
604272, A61M 500
Patent
active
061463612
ABSTRACT:
A needle assembly for a medication delivery pen having a 31 gauge needle cannula that reduces penetration force during an injection process resulting in less pain to the patient without causing any loss in performance or structural integrity.
REFERENCES:
patent: 4313439 (1982-02-01), Babb et al.
patent: 4552561 (1985-11-01), Eckenhoff
patent: 4692142 (1987-09-01), Dignam et al.
patent: 4894054 (1990-01-01), Miskinyar
patent: 4917670 (1990-04-01), Hurley et al.
patent: 4944677 (1990-07-01), Alexandre
patent: 4969884 (1990-11-01), Yum
patent: 4973318 (1990-11-01), Holm
patent: 5015235 (1991-05-01), Crossman
patent: 5151093 (1992-09-01), Theeuwes et al.
patent: 5279586 (1994-01-01), Balkwill
patent: 5295976 (1994-03-01), Harris
patent: 5374256 (1994-12-01), Kriesel
patent: 5462535 (1995-10-01), Bonnichsen et al.
patent: 5540657 (1996-07-01), Kurjan et al.
patent: 5599323 (1997-02-01), Bonnichsen et al.
patent: 5709668 (1998-01-01), Wacks
patent: 5951530 (1999-04-01), Steengaard et al.
patent: 5984906 (1999-11-01), Bonnichsen et al.
Applied Radiology, Jun. 1994, vol. 23, No. 6., advertisement for Ranfac corporation.
The Journal of Pharmacology and Experimental Therapeutics, Dorothea E. Blandford et al., "Role of Vasopressin in Response to Intrarenal Infusions of Alpha-2 Adrenoceptor Agonists", vol. 255, No. 1 (1990).
The Journal of Pharmacology and Experimental Therapeutics, D.D. Smyth et al., Opposite Rank Order of Potency for Alpha-2 Adrenoceptor Agonists on Water and Solute Excretion in the Rat: Two Sites and/or Receptors; vol. 261, No. 3 (1992).
BMJ, "Insulin Injection Technique", Jonathan Thow, et al., vol. 301, Jul. 7, 1990.
Diabetes Care, Anders Frid, et al., "Effects of Accidental Intramuscular Injection on Insulin Absorption in IDDM", 1988, vol. 11, pp. 41-45.
Diabetic Medicine, J.C. Thow, et al., "Insulin Injection Site Tissue Depths and Localization of a Simulated Insulin Bolus Using a Novel Air Contrast Ultrasonographic Technique in Insulin Treated Diabetic Subjects", 1992, pp. 915-920.
Diabetes Care, Per Hildebrandt, et al., "The Absorption of Subcutaneously Injected Short-Acting Soluble Insulin: Influence of Injection Technique and Concentration", 1983, vol. 6, pp. 459-462.
Diabetic Medicine, A. Vaag, et al., "Intramuscular Versus Subcutaneous Injection of Unmodified Insulin: Consequences for Blood Glucose Control in Patients with Type 1 Diabetes Mellitus", 1990, pp. 335-342.
Diabetes Care, Allan Vaag, et al, "Variation in Absorption of NPH Insulin", 1990, vol. 13, pp. 74-76.
Scand J. Caring Science, Lars Engstrom, et al., "Short Communication", 1993, pp. 57-59.
Diabetes Care, Jiten P. Vora, et al., "Relationship Between Absorption of Radiolabeled Soluble Insulin, Subcutaneous Blood Flow, and Anthropometry", 1992, vol. 15, pp. 1484-1493.
Archives of Disease in Childhood, C.P. Smith, et al., "Subcutaneous or Intramuscular Insulin Injections", 1991, pp. 879-882.
Diabetic Medicine, P.H.E.M. de Meijer, et al., "The Variability of Absorption of Subcutaneously Injected Insulin: Effect of Injection Technique and Relation with Brittleness", 1990, pp. 499-505.
Diabetes Care, Michel Polak, et al, "Subcutaneous or Intramuscular Injections of Insulin in Children", 1996, vol. 19, pp. 1434-1436.
Diabetic Medicine, J.C. Thow, et al., "Different Absorption of Isophase (NPH) Insulin from Subcutaneous and Intramuscular Sites Suggests a Need to Reassess Recommended Insulin Injection Technique", 1990 pp. 600-602.
Diabetic Medicine, J.E. Henriksen, et al, "Absorption of NPH (Isophane) Insulin in Resting Diabetic Patients: Evidence for Subcutaneous Injection in the Thigh as the Preferred Site", 1991, pp. 453-457.
Diabetes Care, John P. Bantle, et al., "Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects", 1993, vol. 16, pp. 1592-1596.
Diabetologia, J.E. Henriksen, et al., "Impact of Injection Sites for Soluble Insulin on Glycaemic Control Type 1 (insulin-dependent) Diabetic Patients Treated with a Multiple Insulin Injection Regimen", 1993, pp. 752-758.
Opinion & Order, 96 Civ. 9506 (BSJ), Mar. 9, 1998 (USDC, SDNY). Hypodermic Disposable Needles: Mechanical Properties and Pain Perception as a Function of Needle Diameter: Lene Lytzen Jun. 1991
Photocopy of package for Terumo needle sold in 1989, having needle internal diameter 0.13 to 0.15 mm.
"Announcing The New Micro-Fine IV Pen Needle", pp. BD386-BD 389, published Jul. 1, 1991.
Australian Standard 2145-1985, "Hypodermic Equipment-Hypodermic Needle Tubing", published by The Standards Association of Australia, Jul. 12, 1985, pp. 24-37.
NovoFine 30G 8mm, "NovoFine reduces pain and the risk of intramuscular injections", pp. 18.1-18.4, May, 1993.
United States Court of Appeals for the Federal Circuit Civil Action 98-1312,-1313, Novo Nordisk A/S, Novo Nordisk of North America, Inc., and Novo Nordisk Pharmaceuticals, Inc., v. Eli Lilly and Co., and Becton Dickinson and Company, Decided Feb. 23, 1999.
Insuject-Insuject-X, The Insulin Pens From Nordisk-Wellcome, Freedom of Choice-Freedom of Lifestyle, pp. BD 17378-17383, -BD 17395, c. 1988-1989.
Novolin Pen, Dial-A-Dose Insulin Delivery System, Teaching Manual, Squibb Novo, pp. BD 15360-BD 15373, 1988.
Brochure, "The Outstanding Insulin Cartridge for the Insuject System", BD 017384-BD 017395, c. 1988-1989.
Novo Nordisk A/S, Novo Nordisk of North America, Inc. and Novo Nordisk Pharmaceuticals Inc. v. Becton Dickinson and Company, 96 Civ. 9506 (BSJ), Declarations of Arthur D. Dawson, Ph.D, Red Cassel, and Justin Boylan, and attached Exhibits 47-49.
International Standard, ISO 9626, "Stainless Steel Needle Tubing for Manufacture of Medical Devices ", pp. 2630-2639; Sep. 1, 1991.
The Advanced Approach to Insulin Injection, The Individually Adapted and Flexible Insulin Therapy, BD 000551-BD 000554, Jun., 1987.
"State-of-the-art, Injection Technology from Switzerland", BD000555-000558, 1998.
Advertising Brochure for Terumo 29 Gauge Insulin Syringe, Diabetes Educator, Jan.-Feb. 1989, p. Nov 0034718.
Product Information, Terumo Insulin Syringe, published c. 1989, p. Nov. 0034714.
Novo Nordisk internal memorandum dated Oct. 23, 1989 re: testing of Terumo 29 gauge syringes having measured inner diameter of 0.13-0.15mm.
DiBiasi Michael D.
Harbin Elizabeth A.
West Robert E.
Becton Dickinson and Company
Fiedler Alan W.
Yasko John D.
LandOfFree
Medication delivery pen having a 31 gauge needle does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medication delivery pen having a 31 gauge needle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medication delivery pen having a 31 gauge needle will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2061006